$14.78
0.342.35%
At Close: -
$14.52
-0.26-1.76%
After Hours: 9:02 AM EDT
15 minutes delayed
ITeos Therapeutics
ITOSNASDAQ
ITeos Therapeutics (NASDAQ:ITOS) Stock, Analyst Ratings, Price Targets, Predictions
ITeos Therapeutics Inc has a consensus price target of $41.5, established from looking at the 13 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., JP Morgan, and HC Wainwright & Co. on May 13, 2024, March 12, 2024, and March 7, 2024. With an average price target of $39 between HC Wainwright & Co., JP Morgan, and HC Wainwright & Co., there's an implied 168.60% upside for ITeos Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
JP Morgan
JP Morgan
Wedbush
SVB Leerink
1calculated from analyst ratings
Analyst Ratings for ITeos Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/13/2024 | Buy Now | 216.8% | HC Wainwright & Co. | Swayampakula Ramakanth | $44 → $46 | Maintains | Buy | Get Alert |
| 03/12/2024 | Buy Now | 85.95% | JP Morgan | Brian Cheng | $29 → $27 | Maintains | Overweight | Get Alert |
| 03/07/2024 | Buy Now | 203.03% | HC Wainwright & Co. | Swayampakula Ramakanth | → $44 | Reiterates | Buy → Buy | Get Alert |
| 11/13/2023 | Buy Now | 99.72% | JP Morgan | Daniel Wolle | $32 → $29 | Maintains | Overweight | Get Alert |
| 10/18/2023 | Buy Now | 127.27% | Wedbush | David Nierengarten | → $33 | Reiterates | Outperform → Outperform | Get Alert |
| 08/09/2023 | Buy Now | 203.03% | HC Wainwright & Co. | Swayampakula Ramakanth | $54 → $44 | Maintains | Buy | Get Alert |
| 03/17/2023 | Buy Now | 271.9% | HC Wainwright & Co. | Swayampakula Ramakanth | → $54 | Reiterates | → Buy | Get Alert |
| 03/16/2023 | Buy Now | 120.39% | JP Morgan | Daniel Wolle | $34 → $32 | Maintains | Overweight | Get Alert |
| 03/16/2023 | Buy Now | 127.27% | Wedbush | David Nierengarten | $45 → $33 | Maintains | Outperform | Get Alert |
| 05/13/2022 | Buy Now | 306.34% | SVB Leerink | Daina Graybosch | $60 → $59 | Maintains | Outperform | Get Alert |
| 12/13/2021 | Buy Now | 271.9% | HC Wainwright & Co. | Swayampakula Ramakanth | — | Maintains | Buy | Get Alert |
| 11/12/2021 | Buy Now | 271.9% | SVB Leerink | Daina Graybosch | — | Maintains | Outperform | Get Alert |
| 08/13/2021 | Buy Now | 278.79% | SVB Leerink | — | — | Maintains | Outperform | Get Alert |
FAQ
What is the target price for ITeos Therapeutics (ITOS) stock?
The latest price target for ITeos Therapeutics (NASDAQ:ITOS) was reported by HC Wainwright & Co. on May 13, 2024. The analyst firm set a price target for $46.00 expecting ITOS to rise to within 12 months (a possible 216.80% upside). 6 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for ITeos Therapeutics (ITOS)?
The latest analyst rating for ITeos Therapeutics (NASDAQ:ITOS) was provided by HC Wainwright & Co., and ITeos Therapeutics maintained their buy rating.
When was the last upgrade for ITeos Therapeutics (ITOS)?
There is no last upgrade for ITeos Therapeutics
When was the last downgrade for ITeos Therapeutics (ITOS)?
There is no last downgrade for ITeos Therapeutics.
When is the next analyst rating going to be posted or updated for ITeos Therapeutics (ITOS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ITeos Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ITeos Therapeutics was filed on May 13, 2024 so you should expect the next rating to be made available sometime around May 13, 2025.
Is the Analyst Rating ITeos Therapeutics (ITOS) correct?
While ratings are subjective and will change, the latest ITeos Therapeutics (ITOS) rating was a maintained with a price target of $44.00 to $46.00. The current price ITeos Therapeutics (ITOS) is trading at is $14.52, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.